These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18952556)

  • 1. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
    Yardley DA; Burris HA; Simons L; Spigel DR; Greco FA; Barton JH; Shipley D; Drosick D; Hainsworth JD
    Clin Breast Cancer; 2008 Oct; 8(5):425-31. PubMed ID: 18952556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
    Loesch D; Asmar L; McIntyre K; Doane L; Monticelli M; Paul D; Vukelja S; Orlando M; Vaughn LG; Zhan F; Boehm KA; O'Shaughnessy JA
    Clin Breast Cancer; 2008 Apr; 8(2):178-86. PubMed ID: 18621615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
    Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
    Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
    Yardley DA; Burris HA; Hanson S; Greco FA; Spigel DR; Barton J; Hainsworth JD
    Clin Breast Cancer; 2009 Aug; 9(3):178-83. PubMed ID: 19661042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.
    Stemmler HJ; Kahlert S; Brudler O; Beha M; Müller S; Stauch B; Heinemann V
    Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):630-5. PubMed ID: 16372489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
    O'Shaughnessy JA; Vukelja S; Marsland T; Kimmel G; Ratnam S; Pippen JE
    Clin Breast Cancer; 2004 Jun; 5(2):142-7. PubMed ID: 15245619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
    Hussain MH; MacVicar GR; Petrylak DP; Dunn RL; Vaishampayan U; Lara PN; Chatta GS; Nanus DM; Glode LM; Trump DL; Chen H; Smith DC;
    J Clin Oncol; 2007 Jun; 25(16):2218-24. PubMed ID: 17538166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
    Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ
    J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
    Oudard S; Culine S; Vano Y; Goldwasser F; Théodore C; Nguyen T; Voog E; Banu E; Vieillefond A; Priou F; Deplanque G; Gravis G; Ravaud A; Vannetzel JM; Machiels JP; Muracciole X; Pichon MF; Bay JO; Elaidi R; Teghom C; Radvanyi F; Beuzeboc P
    Eur J Cancer; 2015 Jan; 51(1):45-54. PubMed ID: 25459391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
    Tonyali O; Benekli M; Berk V; Coskun U; Ozkan M; Yildiz R; Ucgul E; Sevinc A; Uncu D; Demirci U; Buyukberber S;
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):981-6. PubMed ID: 23463098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.
    Nasr FL; Chahine GY; Kattan JG; Farhat FS; Mokaddem WT; Tueni EA; Dagher JE; Ghosn MG
    Clin Breast Cancer; 2004 Jun; 5(2):117-22; discussion 123-4. PubMed ID: 15245614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.
    Moulder S; Li H; Wang M; Gradishar WJ; Perez EA; Sparano JA; Pins M; Yang X; Sledge GW
    Breast Cancer Res Treat; 2010 Feb; 119(3):663-71. PubMed ID: 20012354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
    O'Shaughnessy J; Vukelja SJ; Marsland T; Kimmel G; Ratnam S; Pippen J
    Clin Breast Cancer; 2002 May; 3 Suppl 1():17-20. PubMed ID: 12057040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
    Yardley DA; Zubkus JD; Eakle JF; Bechhold RG; Finney L; Daniel D; Daniel B; Hainsworth JD
    Clin Breast Cancer; 2015 Aug; 15(4):251-8. PubMed ID: 25640059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Hainsworth JD; Burris HA; Erland JB; Morrissey LH; Meluch AA; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
    Cancer; 1999 Mar; 85(6):1269-76. PubMed ID: 10189131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
    Miller KD; Sisk J; Ansari R; Gize G; Nattam S; Pennington K; Monaco F; Sledge GW
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):38-40. PubMed ID: 11252888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
    Chan D; Yeo WL; Tiemsim Cordero M; Wong CI; Chuah B; Soo R; Tan SH; Lim SE; Goh BC; Lee SC
    Invest New Drugs; 2010 Dec; 28(6):859-65. PubMed ID: 19705063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.